Enodia Therapeutics

Enodia Therapeutics is a biotechnology company developing best-in-class small-molecule therapies that enable the degradation of disease-driving proteins at the point of synthesis before they have a damaging effect. The company’s platform combines a proteomics-informed understanding of the secretome with machine-learning–enabled selectivity to support rational drug design. Rooted in pioneering research from the Institut Pasteur and built by Argobio Studio, Enodia is advancing a pipeline initially focused on inflammatory and autoimmune diseases, with additional opportunities across oncology and viral infections enabled by the same underlying biological mechanism.